Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
| Title: | Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study |
|---|---|
| Authors: | Yumie Takeshita, Yuki Kita, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Chisato Teramura, Yasufumi Enyama, Toshinari Takamura, the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group |
| Source: | Journal of Diabetes Investigation, Vol 13, Iss 6, Pp 965-974 (2022) |
| Publisher Information: | Wiley, 2022. |
| Publication Year: | 2022 |
| Collection: | LCC:Diseases of the endocrine glands. Clinical endocrinology |
| Subject Terms: | Glucagon‐like peptide‐1 receptor agonists, Glucose toxicity, Insulin–glucagon‐like peptide‐1 receptor agonist relay regimen, Diseases of the endocrine glands. Clinical endocrinology, RC648-665 |
| More Details: | Abstract Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study. To examine this hypothesis clinically, we compared the glucose‐lowering effects of GLP‐1 receptor agonist liraglutide with and without prior glycemic control. Materials and Methods In an open‐label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once‐daily insulin therapy, degludec (Insulin–GLP‐1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GLP‐1 RA, liraglutide (GLP‐1 RA first group, 0.9 mg), for 24 weeks. The primary efficacy end‐points consisted of changes in the levels of fasting plasma glucose and glycated hemoglobin (HbA1c). Results The median fasting plasma glucose and HbA1c before the study were 210.0 mg/dL and 9.8%, respectively. The levels of fasting plasma glucose and HbA1c significantly decreased in the Insulin–GLP‐1 RA relay group (P |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2040-1124 2040-1116 |
| Relation: | https://doaj.org/toc/2040-1116; https://doaj.org/toc/2040-1124 |
| DOI: | 10.1111/jdi.13749 |
| Access URL: | https://doaj.org/article/eaedd379a2fb4663bf3d9039c36984f1 |
| Accession Number: | edsdoj.379a2fb4663bf3d9039c36984f1 |
| Database: | Directory of Open Access Journals |
| ISSN: | 20401124 20401116 |
|---|---|
| DOI: | 10.1111/jdi.13749 |
| Published in: | Journal of Diabetes Investigation |
| Language: | English |